Background. Diabetic nephropathy (DN) represents a devastating complication of diabetes. Family clustering, heterogeneity in the onset and progression and results of segregation studies indicate that susceptibility to DN is a complex trait. Methods. Common single nucleotide polymorphisms in the RAGE (receptor of advanced glycation endproducts) gene (À429T/C, À374T/A, G82S, 1704G/T, 2184A/G and 2245G/A) were studied in the association study comprising 605 Caucasian subjects by means of haplotype analysis in order to identify an eventual haplotype marker for DN in type 2 diabetes. Haplotypes were constructed computationally; frequencies were compared among groups of subjects with type 2 diabetes (DM) and DN, diabetics without DN and non-diabetics. Survival analysis was carried out to ascertain whether certain RAGE haplotypes influence onset of DN in type 2 diabetics. Results. Significant differences in haplotype frequencies among DM þ DN vs DM non-DN and non-DM groups were found (P ¼ 0.0007 and 0.0013, respectively; permutation test). Frequency of the RAGE 2 haplotype containing minor alleles in positions À429 and 2184 (CTGGGG) in the DN group was significantly higher than in the two control groups (21.7% vs 12.8% and 13.8%, both P corr <0.003; two-tail Fisher exact test); odds ratios 1.65 [95% confidence interval (CI): 1.08-2.50; P ¼ 0.020] and 1.79 (95% CI: 1.22-2.62; P ¼ 0.003), respectively. In survival analysis, duration of diabetes until the onset of DN (e.g. appearance of persistent proteinuria) was significantly different among RAGE 2 diplotype groups (P<0.05); median DN-free interval was 9.6 years in RAGE 2 þ/þ homozygotes, 15.2 years in þ/À heterozygotes and 17.0 years in the À/À combination.
Introduction
Diabetic nephropathy (DN) develops as a result of haemodynamic and metabolic changes accompanying diabetes. Most of the hyperglycaemia-driven molecular alterations responsible for the development of diabetic complications in general contribute to some degree to the development of DN. The implication of glycoxidation leading to formation of advanced glycation endproducts (AGEs) in the pathogenesis of DN is well established [1, 2] . AGEs contribute to diabetic tissue injury by both receptor-independent (direct crosslinking of extracellular matrix proteins and modification of intracellular proteins) and receptor-dependent pathways. The latter process is mediated through the interaction with specific cell-surface receptors for AGEs (macrophage scavenger receptor type II, galectin-3, OST-48, 80K-H, CD36 and RAGE). Unlike other receptors, whose function is predominantly scavenging, RAGE possesses a potent signalling role. By virtue of its ability to activate several intracellular pathways leading to the activation of redox-sensitive transcription factor nuclear factor-kB (NFkB), and subsequent NFkB-mediated expression of a number of genes responsible for the alteration of cellular phenotype and function, RAGE actively participates in the processes amplifying tissue injury and sustained inflammation in diabetes [3] .
In the human kidney, likewise in rodent experimental models, RAGE is selectively expressed in podocytes but not in mesangial cells or glomerular endothelium [4] .
Although RAGE has been immunolocalized almost exclusively on podocytes (in both normal and diabetic kidneys), tubular changes at least partly induced by AGE-RAGE interaction were indirectly documented by blockade of AGE-mediated NFkB activation by soluble RAGE or anti-RAGE antibodies [5] . In rodent models, RAGE significantly contributes to glomerular pathology -enhanced permeability, inflammation, mesangial expansion and glomerular basement membrane thickening [6] [7] [8] . Engagement of RAGE by AGEs (and probably also S100/calgranulins) in diabetic kidney contributes through the cascade of signalling events using reactive oxygen species (ROS) as second messengers to the activation of TGF-b, CTGF and VEGF axes directly responsible for renal remodelling. Therapeutic blockade of AGEs, RAGE or the absence of the latter in RAGE-null mice completely suppressed structural and functional changes associated with DN in mice [6, 9] , thereby supporting the pathogenic role of RAGE in DN.
Sequence variation within the RAGE gene has been studied and a relatively large number of single nucleotide polymorphisms (SNPs) in coding and noncoding regions of the RAGE gene have been identified recently ( Figure 1 ). The functional impact of several of them on the transcriptional activity [10] , ligand binding [11] or intermediate phenotype [12] has been described. Several association studies investigated association of selected SNPs in RAGE with complications of diabetes other than DN, mainly with diabetic retinopathy; however, the majority led to negative results. So far, only a limited number of association studies investigated the relationship between RAGE polymorphisms and DN. Selected SNPs (À429T/C, À374T/A and G82S) were studied in type 1 diabetic subjects with DN in the Finnish population; the results indicated a possible protective role of the À374AA genotype for the development of proteinuria and coronary heart disease (CHD) in type 1 diabetes [13] . Japanese authors presented their finding of an association of the 1704G/T RAGE polymorphism together with NAD(P)H p22phox C242T variant with DN; however, this was in a rather limited sample of type 2 diabetic patients [14] . Recently, the 63 bp insertion/deletion variant in the RAGE promoter has been associated with DN in the German population [15] .
With respect to the above-mentioned findings, the RAGE gene is an obvious functional candidate for DN. For the purpose of a future larger multilocus analysis, including among others RAGE, we performed genotyping of all common SNPs in the RAGE gene in order to find a relevant haplotypetagging SNP (htSNP) and eventual marker for DN. One can presuppose that such a short chromosomal segment (spanning $4 kb) harbours tightly linked markers and we might be able to detect htSNPs among them, which could be further tested for association with DN. The aims of our study were to perform SNP-based haplotype analysis of the RAGE gene and, consequently, to try to identify an eventual haplotype marker for DN in type 2 diabetes. Moreover, with respect to the prevalence and incidence data on DN, we performed survival analyses to ascertain whether RAGE SNPs (or haplotypes) influence the onset of DN in type 2 diabetics.
Subjects and methods

Subjects
A total of 605 Caucasian subjects (265 males and 340 females) comprising three groups were enrolled in the association study: (i) type 2 diabetics with parallel DN (DM þ DN); (ii) type 2 diabetics without DN (DM non-DN); and (iii) non-diabetic subjects (non-DM). Clinical characteristics of the study subjects are shown in Table 1 . Diabetic patients were recruited from diabetic outpatient clinics; those with DN were all followed in the specialized nephrology unit of the University Hospital Brno-Bohunice. Non-diabetic subjects were recruited from clients of several general practitioners on the basis of the physician's medical records and physiological results of the fasting glycaemia examination. The selection criteria in both diabetics and non-diabetics respected age and gender-proportion comparability among groups; all subjects derived from the same geographical area and all were of the same ethnic (Caucasian) origin. Informed consent was obtained from all patients prior to their inclusion in the study. The study was performed in accordance with the principles of the Declaration of Helsinki and approved by the Committee for Ethics of Medical Experiments on Human Subjects, Medical Faculty, Masaryk University Brno. 
Diagnosis of diabetic nephropathy
The presence of renal complications was assessed on the basis of the patients' medical history of diabetes (type 2 in this study) with established antidiabetic treatment, medical record from a nephrologist and recent measurement of albumin excretion rate (AER) and glomerular filtration rate (GFR) at the time of enrolment into this study. According to DN clinical criteria based on GFR and AER (or overt proteinuria), subjects with minimally incipient DN (e.g. persistent microalbuminuria) were indicated for regular follow-up in the nephrology unit and, thus, likely to be included in the association study. Diagnosis of DN for the purpose of this study was based solely on the repeated assessment of AER from the 24 h urine collection (used for simultaneous measurement of creatinine clearance) prior to a visit to a nephrologist. A cut-off value of AER !30 mg/24 h (detected repeatedly) was used as an inclusion criterion to the DM þ DN group. However, for the purpose of survival analysis, more-stringent criteria were applied and only those with unequivocal persistent proteinuria (AER !300 g/24 h) were analysed. Negative results of periodical annual screening for microalbuminuria and normal plasma creatinine in the presence of type 2 diabetes were used as criteria for DM non-DN subjects.
Diagnosis of other micro-and macrovascular complications
The presence of diabetic complications other than DN (micro-and macrovascular) was assessed in both DM þ DN and DM non-DN groups by summary comorbidity indexes (micro com and macro com , respectively), where presence of both diabetic retinopathy and/or neuropathy and presence of coronary heart disease (CHD) and/or peripheral vascular disease and/or cerebrovascular disease, respectively, contributed a value of 1 to the index ( Detection of polymorphisms and construction of haplotypes DNA was isolated from peripheral blood leukocytes by a standard extraction method and was available for all subjects enrolled in the study. From all described RAGE substitutions, only those with minor allele frequency (MAF) !1% were studied: À429T/C, À374T/A, G82S, 1704G/T, 2184A/G and 2245G/A. Promoter SNPs À429T/C and À374T/A were genotyped together with the rare À407 to À345 63-bp insertion/deletion from a single polymerase chain reaction (PCR) digested by a mixture of restriction endonucleases. Since this method detects true promoter haplotypes, information about partial phasing could be used in subsequent haplotype construction and improve such estimation. Genotyping was performed according to the methods described elsewhere [10, 12, 16] . Linkage Disequilibrium Analyzer 1.0 (http://www.chgb.org.cn/lda/ lda.htm) [17] was used for analysis of linkage disequilibrium (LD); the pairwise LD measure D 0 was used to describe LD among SNPs. PHASE v. 2.0 [18, 19] and HAPLOTYPER [20] software were used to resolve a sample of phase-unknown multilocus genotypes and to estimate population haplotype frequencies. Due to reported selective advantages of these two Bayesianbased algorithms in some special cases -robustness towards departure from Hardy-Weinberg equilibrium (HWE) (HAPLOTYPER), handling partially experimentally phased subjects and reflecting relative distances between markers (PHASE) -resolving of haplotypes was performed by both algorithms and results were compared. SNPtagger (http://www.well.ox.ac.uk/$xiayi/haplotype/index.html) [21] and HapBlock (http://www.cmb.usc.edu/$msms/HapBlock) [22] programs were used to select htSNPs. If not stated differently, data are expressed as means (±SD). a In the DM non-DN group the duration of diabetes from the time of diagnosis until recruitment to the study is reported. Micro com , microvascular comorbidity summary index, presence of both diabetic retinopathy and/or neuropathy contributes 1 to the index; Macro com , macrovascular comorbidity summary index, presence of CHD and/or peripheral vascular disease and/or cerebrovascular disease contributes 1 to the index.
Statistical analysis
Differences in genotype distributions from those expected for HWE were tested by a 2 test. Differences in allele frequencies of SNPs fulfilling HWE expectation were tested by a two-tail Fisher exact test; otherwise, a 2 test for genotype frequencies was used. Comparison of estimated haplotype frequencies was performed as described [23] by (i) conducting separate one-degree of freedom (df ) tests for a series of 2 Â 2 contingency tables testing the frequency of each specific haplotype vs all others between the two groups (two-tail Fisher exact test) and (ii) omnibus testing of differences in haplotype frequency profiles between the two groups (statistical significance assessed empirically via permutation testing). P<0.05 was considered statistically significant. Testing of allele or genotype frequencies for several SNPs or series of contingency tables for haplotypes among the three groups involves multiple comparisons; therefore, necessary correction had to be applied. Where appropriate, Bonferroni correction was used to adjust the a level according to the number of independent comparisons to an overall value of 0.05. Adjusted P-values for particular analyses are denoted as P corr . Additionally, haplotype-specific effects were analysed by logistic regression-based algorithm, as described by Zhao et al. [24] .
Survival analysis in a group of diabetic patients was performed using the Kaplan-Meier method and Cox's proportional hazard model. The aim of the survival analysis was to retrospectively analyse the relationship between haplotype and duration of DN (assessed according to personal history of DN in each diabetic). Kaplan-Meier survival curves were constructed for three RAGE 2 haplotype groups (homozygous RAGE 2 þ/þ, heterozygous RAGE 2 þ/À and homozygous RAGE 2 À/À). Subjects with DN (subgroup of DM þ DN with AER !300 g/24 h) were classified as complete responses, others as censored; survival represented duration of DM until the onset of DN in complete responses or DM duration until the recruitment to the study in censored responses. Survival was compared among multiple groups and post-hoc comparisons were made between pairs of groups (log rank test).
Variation of selected biochemical and clinical parameters corresponding to particular genotypes was tested by Kruskal-Wallis analysis of variance (ANOVA) and Spearman correlation coefficient. For all statistical analyses, STATISTICA for Windows Õ (Statsoft Inc., Tulsa, OK, USA) was used.
Results
Genotype and allele frequencies of all polymorphisms studied are given in Table 2 . Data analysis employed the following strategies: (i) single-locus analyses of genotype data and LD assessment; (ii) in silico inferring of haplotypes and comparison of their frequencies among groups; (iii) analysis of duration data by survival analysis; and (iv) analysis of genetic data in relation to the clinical and biochemical phenotype.
Single-locus analyses
After the correction for multiple comparisons, there were neither significant deviations from HWE nor any significant differences in allele or genotype frequencies between groups ( Table 2) . Frequencies of the À429C and 2184G alleles were, however, higher in the DN group (22.0% vs average 16.3% in control groups and 23.0% vs average 15.2%, respectively). Allele frequencies of the 63 bp insertion/deletion polymorphism obtained as a by-product of promoter genotyping were 99.2% insertion, 0.8% deletion in both DM þ DN and DM non-DN and 99.6% insertion, 0.4% deletion in non-DM. Figure 2 displays results of LD assessment in the whole sample and the three groups separately. The pairwise LD values described by Lewontin's D 0 suggested that most of the SNPs are in strong LD. However, some SNPs (namely the G82S) showed relatively low LD with markers of suggestive association with DN (À429T/C and 2184A/G), see arrows in Figure 2 . Low LD together with the low frequency of G82S might suggest distant origin and possible independency of this SNP on common haplotypes in the RAGE gene. Alternatively, low LD could be due to a high mutation rate in the particular gene region. However, there are no indications that the G82S is localized in a mutation hotspot.
In silico haplotyping and haplotype analysis
Experimental phasing (molecular haplotyping) of all individuals was only available for 5 0 UTR polymorphisms detected by allele-specific PCR (À429T/C and À374T/A). However, for inferring and comparing haplotype frequencies we theoretically considered the whole genotype set as unphased and promoter haplotypes were used only for the control purposes and for reverse classification of subjects for survival analysis (the Àk option in PHASE v. 2.0). Inferring haplotypes from unphased genotype data was performed computationally using HAPLOTYPER and PHASE v. 2.0 software packages with the assumption of mutual independence of haplotypes. Implementing the information about partial phasing of individuals and performing the case-control comparison simultaneously might make PHASE the algorithm of choice. Nevertheless, in silico haplotyping was performed by both types of software. Practically, PHASE was run with a single file including genotypes of all subjects; for c-option (three groups), 10 000 permutations were performed. HAPLOTYPER was run with 30 rounds on each group of subjects and on pooled case-control groups (due to the limitation of maximal allowed number of subjects). Completeness of genotype data was nearly 100% (total of five missing genotypes). Table 3 shows haplotype frequency estimates in particular groups. Haplotypes were denoted RAGE x where x represents ordinal number of inferred haplotype (total x ¼ 10 in DM þ DN group; x ¼ 11 in the other two groups). Using permutation testing (PHASE, 10 000 permutations), we found significant omnibus differences in haplotype frequencies between DM þ DN vs DM non-DN groups and DM þ DN vs non-DM groups (both P ¼ 0.0007 and P ¼ 0.0013, respectively). 
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Differences among the two control groups were not found. RAGE 2 (CTGGGG) and RAGE 8 (CTGGAG) haplotype frequencies accounted for the greatest part of the difference in both comparisons (all P corr <0.003). Particularly, the frequency of the RAGE 2 in the DM þ DN group was markedly higher than in the two control groups (21.7% vs 12.8% and 13.8%, respectively). The frequency of RAGE 8 in the DM þ DN group was, conversely, lower than expected; this haplotype had, however, an incomparably lower population frequency than common haplotype RAGE 2 and its eventual effect is, therefore, likely to be minor.
In addition to the global test for haplotype association, we also estimated the haplotype-specific effects of each haplotype on disease risk. The latter was performed by the method described by Zhao et al. [24] , which allows for joint estimation of haplotype distribution and its correlation with disease phenotype via logistic regression. The best reconstructed haplotypes are treated as covariates in logistic regression analysis. Estimated odds ratios (ORs) and 95% confidence intervals (CIs) for common haplotypes are shown in Table 3 . Comparison of the DM þ DN group with the DM non-DN and the non-DM group revealed for RAGE 2 haplotype ORs 1.65 (95% CI: 1.08-2.50; P ¼ 0.020) and 1.79 (95% CI: 1.22-2.62; P ¼ 0.003), respectively [for pooled control groups, OR ¼ 1.72 (95% CI: 1.22-2.42; P ¼ 0.002)], indicating again a significant increase of relative risk of DN associated with this haplotype. We therefore conclude that this common haplotype, associated with DN, could be regarded as a marker for DN.
Identification of htSNPs
Substitutions at positions À429 and, especially, 2184 are obviously htSNPs for the common haplotype RAGE 2 . To select efficient htSNPs in the RAGE gene more rigorously, we applied two algorithms proposed by Ke and Cardon [21] and Zhang et al. [22] . With both programs, htSNPs were selected to explain an interval of 100-50% of the haplotype diversity given the SNPs analysed. Results are displayed in Table 4 . Depending on the particular study requirements, one can ignore uncommon haplotypes by setting a haplotype 'coverage value' less than 1.0. Table 3 . Multilocus haplotype frequency estimates and results of comparison of estimated haplotype frequencies. Haplotypes are ordered according to decreasing haplotype frequency in the DM þ DN group, those with frequencies <1% in all three groups were pooled together as 'others'. Estimates of frequencies given in absolute numbers (according to HAPLOTYPER), percentages in parentheses (HAPLOTYPER/PHASE). Separate one-degree of freedom tests were conducted for a series of 2 Â 2 contingency tables testing the frequency of each specific haplotype vs all others between particular groups (two-tail Fisher exact test, 20 independent observations, Bonferroni-corrected P-value for single test equals to 0.003). ORs and 95% CIs for common haplotypes were estimated by logistic regression analysis, treating the best-reconstructed haplotypes as covariates. Global differences in haplotype frequency profiles between particular groups were tested by permutation testing (PHASE output, 10 000 permutations) Omnibus P-value assessed empirically by permutation testing. 
Survival analysis
Using the Kaplan-Meier method, survival functions were constructed for three groups of subjects classified according to the RAGE 2 diplotype (carriers of two, one and zero copies of the RAGE 2 haplotype). Naturally, unambiguous reverse classification of estimated haplotypes into real genotypes in each individual subject was not possible; nevertheless, with the help of estimates of the most probable haplotype pairs for each individual produced by PHASE, weighed against their posterior probabilities, survival analysis was performed in a subset of diabetic subjects where classification of the RAGE 2 genotype was sufficiently reliable. Presence of two (þ/þ) or zero copies (À/À) of the RAGE 2 haplotype was clearly distinguishable. For compound heterozygotes À429T/C, 2184 A/G, minor alleles in the RAGE 2 haplotype could theoretically be mutually in either cis or trans orientation (e.g. C-G/T-A or C-A/ T-G, respectively). However, the trans position was not once estimated computationally in the whole sample; therefore, we assumed solely cis orientation (e.g. C-G/T-A combination only) accordingly. Survival analysis was performed twice: first (A), including all available subjects classified for the number of RAGE 2 copies (þ/þ, þ/À and À/À), irrespective of the presence of other haplotypes in heterozygotes and non-RAGE 2 homozygotes; and, second (B), in a subset of subjects bearing only RAGE 1 haplotypes or those with variants with MAF <10% in combination with RAGE 2 in heterozygotes and À/Àhomozygotes. Analysis B should exclude possible interfering effects of other common haplotypes on survival.
Practically, from the total number of diabetic subjects (n ¼ 377), those with persistent proteinuria (AER !300 g/24 h) were classified as complete responses (n ¼ 99) and others as censored (n ¼ 278). Reliable reverse classification of RAGE 2 haplotypes into genotypes was reliable in all subjects (posterior probabilities for both individual's estimated haplotypes >95%) Fig. 3 . Results of survival analysis. Kaplan-Meier curves for the RAGE 2 diplotype groups. Diabetic subjects with AER !300 g/24 h classified as complete responses, others as censored. DN-free interval ('survival') represents duration of DM till the onset of DN in complete responses or DM duration till the recruitment to the study in censored responses. RAGE 2 diplotypes were classified on the basis of PHASE estimates as the most probable haplotype pairs for each individual weighed against their posterior probabilities (for all included subjects P ! 0.95). Comparison A included all available subjects classified for RAGE 2 haplotype, irrespective of the presence of other haplotypes in heterozygotes and non-RAGE 2 homozygotes; comparison B included a subset of subjects bearing in heterozygote and wildtype homozygote diplotypes only RAGE 1 haplotypes or those containing rare variants (MAF<10%) in combination with RAGE 2 . Reported P-values apply to comparison of the DN-free interval among the three RAGE 2 diplotype groups. Table 2 . Alternative markers without additional information shown in brackets RAGE polymorphisms and diabetic nephropathy 1099 and was performed as described above. Data required for survival analysis (DN-free interval) were available in 90 complete responses (duration of diabetes till the onset of persistent proteinuria) and 201 censored (DM duration till the recruitment to the study). Figure 3 shows the Kaplan-Meier plots of survival functions for the three RAGE 2 diplotype groups in the larger (A) and smaller (B) subsets of subjects. The duration of diabetes until the onset of DN, e.g. DN-free interval, was significantly different among RAGE 2 diplotype groups in both A and B comparisons ( 2 ¼ 7.67, df ¼ 2, P ¼ 0.021 and 2 ¼ 6.61, df ¼ 2, P ¼ 0.037, respectively). The median DN-free intervals in A (and B) comparisons were 9.6 (9.6) years in RAGE 2 þ/þ homozygotes, 17.8 (15.2) years in þ/À heterozygotes and 18.9 (17.0) years in the À/À combination. Post-hoc testing revealed a significant difference between RAGE 2 þ/þ vs À/À and þ/þ vs þ/À groups in both A and B comparisons (all P<0.05; log rank test). RAGE 2 þ/À vs À/À did not differ significantly. Survival time was a function of neither age nor gender in any genotype group.
Analysis of genetic data in relation to the clinical and biochemical phenotype
Neither micro-nor macrovascular comorbidity (micro com and macro com indexes) was significantly different among particular RAGE 2 haplotype groups tested in the two diabetic groups separately as well as in the pooled group (Spearman correlation coefficient). Similarly, urea, creatinine, proteinuria and GFR did not differ among particular RAGE 2 groups (KruskalWallis ANOVA).
Discussion
Glycoxidation represents one of the principal pathogenic mechanisms of hyperglycaemia-induced cell damage in both types of diabetes. Hyperglycaemia substantially enhances oxidative stress and the AGE/RAGE system is one of the most important non-mitochondrial contributors. AGEs generate ROS directly or through their receptors, presumably by intracellular cooperation of RAGE with membranebound NAD(P)H oxidase [25] . An abundance of AGE ligands in the diabetic milieu and the unequivocal role of RAGE in the pathogenesis of DN, together with the identification of extensive polymorphism within its coding and non-coding regions, logically focused attention on the study of association of genetic variability in the RAGE gene with diabetic complications.
Family clustering, apparent heterogeneity in the onset and progression of DN in both type 1 and 2 diabetes and the results of segregation studies indicate that genetic factors contribute to susceptibility to DN. Several linkage studies attempted to find the susceptibility locus for DN. A locus in chromosome 6p21.3, where RAGE lies, has not been identified as one of them. However, the majority of linkage studies were performed with a prior candidate gene hypothesis; therefore, they were not truly genome-wide. Besides, linkage studies in type 2 diabetes encounter substantial problems arising from late manifestation of disease. The possibility that RAGE is not only a functional but also a positional candidate for DN could not, therefore, be ruled out.
Complex disease gene mapping via case-control studies faces several methodological and statistical considerations. Studies of individual SNPs geneby-gene are a widely used, simple, easy to interpret approach and certainly legitimate in the initial stage, when it could identify variants with strong marginal effects. In studies where association of more than one SNP is investigated, correction for multiple comparisons causes a poor outcome, because SNPs without informative value worsen results. At the same time, tightly linked SNPs are incorrectly treated as independent. Thus, analysis of haplotypes is a theoretically better approach; however, unambiguous reconstruction of haplotypes from genotype data is not possible (for multiple heterozygotes) and, consequently, eventual reverse classification into haplotypebased diplotypes is also more or less approximate, based on haplotype estimates and posterior probabilities. Due to these reasons, haplotype analyses are likely to slightly overstate eventual statistical significance.
Due to the limited power of conventional singlelocus analysis and its logical shortcomings in the case of several linked SNPs within one gene, but aware of the above mentioned inaccuracy, we preferred a 'haplotype-centric' approach. In the present study, we examined the relationship between the genetic variability in the RAGE gene and DN accompanying type 2 diabetes in a Caucasian population. We tried to preserve as much of the SNP information content as possible without immoderate decrease of statistical power. Our results demonstrate first of all (i) significantly increased prevalence of RAGE 2 haplotype (consisting of alleles À429C/À374T/82G/1704G/ 2184G/ 2245G) in the DN group (21.7% in DN vs 13.4% in control groups) in the situation of (ii) statistically formally non-significant single-locus association of the À429T/C and 2184A/G SNPs. Moreover, (iii) the RAGE 2 haplotype was not only associated with DN as such [with relative risk associated with RAGE 2 haplotype corresponding to an OR ¼ 1.72 (95% CI: 1.22-2.42; P ¼ 0.002)], but its presence was significantly associated with acceleration of the onset of DN with the biological gradient corresponding to the number of RAGE 2 copies in each individual group. However, this effect did not correspond with classical clinical markers of DN. Proteinuria and decline of renal function are probably net results of a series of events implicated in the pathogenesis of DN rather than relevant intermediate phenotype for the gene studied.
Ascertained haplotype association could either indicate presence of the true causal variant within the haplotype or indirectly reflect existence of a causal marker located in the vicinity of the haplotype (in the same but probably another gene). Although the latter is usually the case, available functional data about RAGE are in favour of the hypothesis that the ascertained association might be causal. Allele T of the À429T/C polymorphism was shown to have a 2-fold transcriptional activity compared with the C allele [10] and the 2184A/G substitution in intron 8 was associated with antioxidant status in diabetics [12] . Of particular interest is the finding that not a single association of any of the two SNPs separately but joint occurrence in the RAGE allele contributed to the DN susceptibility in our study. Cis-interaction between the two variants might be one plausible explanation. In the light of recent findings of the existence of tissue-specific alternative splicing of RAGE mRNA leading to the endogenous production of N-and C-truncated forms of RAGE [26] [27] [28] , it might be possible that cisinteraction between promoter and intron 8 variant participate in the regulation of that process. It was shown that alternative splicing involves areas spanning exon 10 and introns 6 and 9 of the RAGE gene; htSNP 2184A/G in intron 8 could be hypothetically situated within the regulatory element binding site and participate in a regulatory role. Competition of translational products of the full-length RAGE transcript with its soluble alternative transcript for the AGEs could determine the extent of distal effects following ligand binding. Summarily, the RAGE 2 haplotype could represent a 'gain-of-function' variant, whose presence in a particular diabetic subject, especially in homozygous form, contributes to the susceptibility to develop DN. Judging by its fairly common population frequency, we might speculate that this haplotype could bring some selective advantage (prompt innate immune response, for example). However, in agreement with Yonekura et al. [28] , 'diabetes abuses the molecular devices of the RAGE signalling pathway primarily evolved for other physiological processes' and turns them into pathogenic factors.
Several limitations of our study have to be mentioned. First, the number of subjects was not sufficiently large enough to detect an eventual association between DN and polymorphisms with lower frequencies (G82S and 1704G/T); power analysis (data not shown) was conducted to estimate a sample size large enough to detect differences in allele frequencies of SNPs with MAF !10% (according to published frequencies by Kankova et al. [16] and Hudson et al. [10] ). However, single-locus analysis has not been our primary goal and, besides, such a low population frequency does not correspond with those expected for the proposed model of inheritance. Second, the control group of diabetics without DN had, on average, a shorter duration of diabetes. This is a serious argument potentially weakening our conclusions, as one could expect future development of DN at least in some of the control subjects. However, with respect to the equal mean age in both groups, genetic similarity of the DM non-DN group with non-diabetics and a rather random diagnosis of type 2 diabetes, we could hypothesize that either DM developed later in life or was clinically silent for a longer time and, thus, undiagnosed because those subjects do not belong to the high-risk group. For control purposes, all analyses mentioned above were performed on the subset of DM þ DN with duration of DM <10 years and DM non-DN with duration >10 years yielding analogous results to those for the whole diabetic group with the exception of even more pronounced HWE violation for the À429T/C in DN group (data not shown). Nevertheless, this issue deserves further attention and recruitment of a large control group of subjects with long duration of diabetes without chronic complications is currently ongoing.
In conclusion, the presented data indicate that the RAGE 2 haplotype containing minor alleles at positions À429 and 2184 and major allele at position À374 could be regarded as a marker for DN; consequently, variant À374T/A plus one of the two SNPs À429T/C or 2184A/G could be considered htSNPs for the RAGE gene covering a large proportion of haplotype diversity and used in future studies examining association of RAGE with disease phenotypes. Experimental evidence of the RAGE pathogenic involvement, consistency of association of genetic variability in RAGE with DN (allelic heterogeneity in different ethnic groups, though) and the observed negative correlation of the DN-free interval and the number of RAGE 2 haplotype copies support the hypothesis that the reported association could be causal.
